Complement biology for hematologists

被引:16
作者
Duval, Anna [1 ,2 ]
Fremeaux-Bacchi, Veronique [1 ,3 ]
机构
[1] Ctr Rech Cordeliers, Inserm, UMR S1138, Paris, France
[2] Univ Hosp Strasbourg, Dept Nephrol Dialysis & Transplantat, Strasbourg, France
[3] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Serv Immunol, Paris, France
关键词
PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMOLYTIC-UREMIC SYNDROME; SICKLE-CELL-DISEASE; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; FACTOR-H; IMMUNE THROMBOCYTOPENIA; INHIBITOR ECULIZUMAB; TRANSFUSION REACTION; TERMINAL COMPLEMENT;
D O I
10.1002/ajh.26855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The complement system is part of the innate immunity. An increased activation or a loss of the regulation of this fine-tuned cascade is involved in a variety of hematological diseases. During the last decade, anti-C5 therapies have revolutionized the management and prognosis of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic and uremic syndrome (aHUS). The availability of a rapidly growing number of innovative complement inhibitors has opened new therapeutic perspectives for several other hematological disorders in which the complement is involved at different degrees. This review focuses on complement biology and its mechanisms of activation in hematological diseases.
引用
收藏
页码:S5 / S19
页数:15
相关论文
共 148 条
[1]   Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab A case report [J].
Abe, Tomohiro ;
Sasaki, Akira ;
Ueda, Taichiro ;
Miyakawa, Yoshitaka ;
Ochiai, Hidenobu .
MEDICINE, 2017, 96 (06)
[2]   C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19 [J].
Aiello, Sistiana ;
Gastoldi, Sara ;
Galbusera, Miriam ;
Ruggenenti, Piero ;
Portalupi, Valentina ;
Rota, Stefano ;
Rubis, Nadia ;
Liguori, Lucia ;
Conti, Sara ;
Tironi, Matteo ;
Gamba, Sara ;
Santarsiero, Donata ;
Benigni, Ariela ;
Remuzzi, Giuseppe ;
Noris, Marina .
BLOOD ADVANCES, 2022, 6 (03) :866-881
[3]  
Arinsburg S A, 2010, Immunohematology, V26, P87
[4]   The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management [J].
Artinger, Katharina ;
Hackl, Gerald ;
Schilcher, Gernot ;
Eisner, Florian ;
Pollheimer, Marion J. ;
Mache, Christoph ;
Weiss, Eva-Christine ;
Eller, Kathrin ;
Eller, Philipp .
BMC NEPHROLOGY, 2019, 20 (1)
[5]   Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome [J].
Bazzan, Mario ;
Todros, Tullia ;
Tedeschi, Silvana ;
Ardissino, Gianluigi ;
Cardaropoli, Simona ;
Stella, Stefania ;
Montaruli, Barbara ;
Marchese, Cristiana ;
Roccatello, Dario ;
Cugno, Massimo .
THROMBOSIS RESEARCH, 2020, 196 :167-174
[6]   Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals [J].
Becarevic, Mirjana .
CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (07)
[7]   Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease [J].
Belcher, John D. ;
Chen, Chunsheng ;
Julia Nguyen ;
Milbauer, Liming ;
Abdulla, Fuad ;
Alayash, Abdu I. ;
Smith, Ann ;
Nath, Karl A. ;
Hebbel, Robert P. ;
Vercellotti, Gregory M. .
BLOOD, 2014, 123 (03) :377-390
[8]   Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? [J].
Berentsen, Sigbjorn ;
Barcellini, Wilma ;
D'Sa, Shirley ;
Jilma, Bernd .
IMMUNOTHERAPY, 2022, 14 (15) :1191-1204
[9]   Role of Complement in Autoimmune Hemolytic Anemia [J].
Berentsen, Sigbjorn .
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2015, 42 (05) :303-310
[10]   Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease [J].
Bhunia, Nabanita ;
Abu-Arja, Rolla ;
Bajwa, Rajinder P. S. ;
Auletta, Jeffery J. ;
Rangarajan, Hemalatha G. .
PEDIATRIC BLOOD & CANCER, 2019, 66 (10)